Skip to main navigation
Eiger - Header Menu
About
Team
Investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
Corporate Governance
Shareholder Services
Analyst Coverage
Programs
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Avexitide for Congenital Hyperinsulinism (CHI)
Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
Resources
Expanded Access Policy
Contact Us
Privacy Policy
Terms of Use
Eiger - Header Menu
About
Team
Investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
Corporate Governance
Shareholder Services
Analyst Coverage
Programs
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Avexitide for Congenital Hyperinsulinism (CHI)
Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
Resources
Expanded Access Policy
Contact Us
Privacy Policy
Terms of Use
Investors
Event Details
Q2 2022 Eiger BioPharmaceuticals Financial Results Call
August 04, 2022
Click here for webcast
Tools
Print Page
Contact Us
RSS Feeds
Email Alerts
IR Contacts
